ArticlePloS one2017
Assessment of circulating copy number variant detection for cancer screening.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 39 citations in OpenAlex.
- Establishment and Performance Evaluation of a Multiplexed TET2-APOBEC-Mediated cfDNA Methylation Detection Workflow Using qPCR and dPCR Readouts.Journal of personalized medicine · 2026Article
- Integrative fragmentomic and mutational signature profile of plasma cfDNA for early lung cancer detection.NPJ precision oncology · 2026Article
- Liquid biopsy, multi-cancer early detection, and artificial intelligence: new frontiers in cancer screening from a technological and immunological perspective.Frontiers in immunology · 2026Review
- Accurate and Efficient Detection of Nasopharyngeal Carcinoma Using Multi-Dimensional Features of Plasma Cell-Free DNA.Head & neck · 2025Article
- Analytical evaluation of circulating tumor DNA sequencing assays.Scientific reports · 2024Article
- Non-invasive detection of lymphoma with circulating tumor DNA features and protein tumor markers.Frontiers in oncology · 2024Article
- A non-invasive method for concurrent detection of multiple early-stage cancers in women.Scientific reports · 2023Article
- A novel approach for the non-invasive diagnosis of pulmonary nodules using low-depth whole-genome sequencing of cell-free DNA.Translational lung cancer research · 2022Article
- Prognostic significance of copy number variation in B-cell acute lymphoblastic leukemia.Frontiers in oncology · 2022Review
- Copy Number Variation of Circulating Tumor DNA (ctDNA) Detected Using NIPT in Neoadjuvant Chemotherapy-Treated Ovarian Cancer Patients.Frontiers in genetics · 2022Article
- Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer.Reproductive biology and endocrinology : RB&E · 2021Review
- Properties and Application of Cell-Free DNA as a Clinical Biomarker.International journal of molecular sciences · 2021Review
- Cell-free tumour DNA analysis detects copy number alterations in gastro-oesophageal cancer patients.PloS one · 2021Article
- Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy.Scientific reports · 2020Article
- Machine learning-based genome-wide interrogation of somatic copy number aberrations in circulating tumor DNA for early detection of hepatocellular carcinoma.EBioMedicine · 2020Article
- Joint single cell DNA-seq and RNA-seq of gastric cancer cell lines reveals rules ofNAR genomics and bioinformatics · 2020Article
- Circulating tumor DNA as an early cancer detection tool.Pharmacology & therapeutics · 2020Review
- Somatic copy number profiling from hepatocellular carcinoma circulating tumor cells.NPJ precision oncology · 2020Article
- Cell-free DNA for genomic profiling and minimal residual disease monitoring in Myeloma- are we there yet?American journal of blood research · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Current high-sensitivity cancer screening methods, largely utilizing correlative biomarkers, suffer from false positive rates that lead to unnecessary medical procedures and debatable public health benefit overall. Detection of circulating tumor DNA (ctDNA), a causal biomarker, has the potential to revolutionize cancer screening. Thus far, the majority of ctDNA studies have focused on detection of tumor-specific point mutations after cancer diagnosis for the purpose of post-treatment surveillance. However, ctDNA point mutation detection methods developed to date likely lack either the scope or analytical sensitivity necessary to be useful for cancer screening, due to the low (<1%) ctDNA fraction derived from early stage tumors. On the other hand, tumor-derived copy number variant (CNV) detection is hypothetically a superior means of ctDNA-based cancer screening for many tumor types, given that, relative to point mutations, each individual tumor CNV contributes a much larger number of ctDNA fragments to the overall pool of circulating free DNA (cfDNA). A small number of studies have demonstrated the potential of ctDNA CNV-based screening in select cancer types. Here we perform an in silico assessment of the potential for ctDNA CNV-based cancer screening across many common cancers, and suggest ctDNA CNV detection shows promise as a broad cancer screening methodology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.